Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 20/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 19/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 18/20 | 0.68 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7887839 | 0.84 | OPRL1 (0.65) | OPRL1OPRM1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL7886448 | 0.83 | OPRL1 (0.64) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL2240264 | 0.81 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL29707895 | 0.81 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL15807233 | 0.81 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3898784 | 0.81 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL29579414 | 0.81 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL2240259 | 0.81 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL8186716 | 0.81 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL7885527 | 0.80 | OPRL1 (0.98) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642247-B2 | Treting anxiety, stress, depression, trauma, Alzheimer's mediated memory loss, epilepsy, arterial blood pressure disorders, obesity, acute pain, chronic pain, Na+ excretion, control of water balance, and symptoms associated with drug | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-0963985-B1 | Di-or triaza-spiro(4,5)decane derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-12 | — | — | EP | disclosed |
| EP-0963985-A2 | Di-or triaza-spiro(4,5)decane derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | NPY4R, NPY1R, OXER1 | OPRL1 36/4885OPRM1 152/4885OPRK1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.